iJournal Club - Lung Cancer: 2013Feasibility of a biology-driven trial based on baseline tumor ERCC1 protein levels and EGFR mutations in the adjuvant setting (Abstract)
Key Points
Dr Love’s Take
This creatively designed and highly anticipated prospective trial essentially failed because of the lack of reproducibility of the ERCC1 assay. These findings provide an important lesson not only about the potential pitfalls of molecular assessments but also the temptation to move early data into clinical practice (which a fair number of clinicians did with ERCC1). Ironically, perhaps what was most clinically useful about this study was learned from the control arm of cisplatin/pemetrexed, on which the tolerability of treatment and intended dose delivery closely mirrored findings from the TREAT study (also discussed in this interactive monograph). In that regard, the study supports the common practice of using cisplatin/pemetrexed in the adjuvant treatment of lung adenocarcinoma. |